文献速递头颈与中枢神经肿瘤

帕博利珠单抗联合或不联合贝伐珠单抗治疗铂类耐药复发或转移性鼻咽癌:一项随机、开放标签、2期试验

Pembrolizumab with or without bevacizumab in platinum-resistant recurrent or metastatic nasopharyngeal carcinoma: a randomised, open-label, phase 2 trial.
PubMed 文献 · Lancet Oncol · 2025-01-15

这项在新加坡两家医院开展的随机、开放标签、2期试验纳入48例铂类耐药复发或转移性鼻咽癌患者,按1:1随机接受帕博利珠单抗单药或帕博利珠单抗联合贝伐珠单抗治疗。联合组客观缓解率显著高于单药组(58.3% vs 12.5%,未校正RR 4.67,p=0.0010)。联合组3级治疗相关不良事件发生率为29%,单药组为8%,两组均无4级治疗相关不良事件或治疗相关死亡。

要点

  • 联合组客观缓解率58.3%,单药组12.5%,未校正RR 4.67(95%CI 1.54-14.18),p=0.0010。
  • 联合组3级治疗相关不良事件7例(29%),单药组2例(8%),两组均无4级事件或治疗相关死亡。
  • 作者认为若在3期试验中验证,联合方案可能成为该人群新的标准治疗。

核心结论

  • 帕博利珠单抗联合贝伐珠单抗较帕博利珠单抗单药更有效,且毒性可控,用于铂类耐药鼻咽癌。
  • 作者认为若在3期试验中验证,该联合治疗可能成为该患者人群新的标准治疗。

研究设计与样本

  • 随机、开放标签、2期试验,在新加坡两家医院(National University Cancer Institute和Tan Tock Seng Hospital)开展。
  • 纳入21岁及以上、ECOG体能状态0-1的铂类耐药复发或转移性鼻咽癌患者48例,按1:1随机分配。

主要发现

  • 联合组客观缓解率为58.3%(95%CI 36.6-77.9),单药组为12.5%(95%CI 2.7-32.4),未校正RR 4.67(95%CI 1.54-14.18),p=0.0010。
  • 联合组3级治疗相关不良事件7例(29%),单药组2例(8%);两组均无4级治疗相关不良事件或治疗相关死亡。
  • 联合组血栓或出血4例(17%),单药组0例;联合组高血压1例(4%),单药组0例;联合组蛋白尿1例(4%),单药组0例。
  • 单药组结肠炎1例(4%),联合组0例;单药组转氨酶升高1例(4%),联合组0例;联合组血细胞减少1例(4%),单药组0例;单药组皮肤毒性1例(4%),联合组0例。

关键数值与推荐

  • 帕博利珠单抗200 mg静脉注射,每21天一次;贝伐珠单抗7.5 mg/kg静脉注射,于每剂帕博利珠单抗前1周给药。
  • 治疗持续至影像学疾病进展、不可接受毒性、完成32个周期或撤回知情同意。
  • 主要终点为客观缓解率,由独立放射科医师按RECIST版本1.1评估,在意向治疗人群中分析。

临床怎么用

  • 作者认为帕博利珠单抗联合贝伐珠单抗在铂类耐药鼻咽癌中较单药更有效且毒性可控。
  • 作者认为若在3期试验中验证,该联合治疗可能成为该患者人群新的标准治疗。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Vascular endothelial growth factor (VEGF) is overexpressed in nasopharyngeal carcinoma and suppresses the anti-tumour immune response. Previous studies have shown that adding anti-VEGF treatment to PD-1 inhibition treatment strategies improves tumour response. We aimed to compare the efficacy of pembrolizumab, a PD-1 inhibitor, with or without bevacizumab, a VEGF inhibitor, in nasopharyngeal carcinoma. METHODS: In this randomised, open-label, phase 2 trial done at two hospitals (National University Cancer Institute and Tan Tock Seng Hospital) in Singapore, patients with platinum-resistant recurrent or metastatic nasophayngeal carcinoma were eligible if they were aged 21 years or older and had an Eastern Cooperative Oncology Group (ECOG) performance status of 0-1. Patients were assigned (1:1; using random permuted blocks with varying sizes of 4 and 6) to receive either intravenous pembrolizumab (200 mg) every 21 days or a combination of pembrolizumab with intravenous bevacizumab (7·5 mg/kg) administered 1 week prior to each dose, until radiographic disease progression, unacceptable toxicity, completion of 32 cycles, or withdrawal of consent. The study was open label, therefore no masking of treatment assignment was implemented. The primary endpoint was objective response rate, assessed using RECIST (version 1.1) by independent radiologists and analysed in the intention-to-treat population (ie, all randomly assigned patients). This trial is registered with ClinicalTrials.gov, NCT03813394, and enrolment has closed. FINDINGS: Between May 13, 2019, and Dec 6, 2023, we assessed 60 individuals for eligibility, 12 were excluded, and 48 were randomly allocated to pembrolizumab alone (n=24) or a combination of bevacizumab and pembrolizumab (n=24). The median age was 56 years (IQR 48-65), and 40 (83%) of 48 patients were male and eight (17%) were female. The median follow-up was 28·3 months (IQR 15·1-55·9). The objective response rate was significantly higher in the bevacizumab and pembrolizumab group (58·3% [95% CI 36·6-77·9] than in the pembrolizumab group (12·5% [2·7-32·4]; unadjusted RR 4·67 [95% CI 1·54-14·18]; p=0·0010). Grade 3 treatment-related adverse events occurred in two (8%) of 24 patients in the pembrolizumab group and in seven (29%) of 24 patients in the bevacizumab and pembrolizumab group; the most common severe or grade 3-4 treatment-related adverse events were thrombosis or bleeding (four [17%] of 24 patients in the bevacizumab and pembrolizumab group vs none of 24 patients in the pembrolizumab group), and others were transaminitis (none vs 1 [4%]), colitis (1 [4%] vs none]), cytopenias (none vs 1 [4%]), dermatological toxicities (1 [4%] vs none]), hypertension (1 [4%] vs none]), and proteinuria (1 [4%] vs none]). There were no grade 4 treatment-related adverse events or treatment-related deaths in either group. INTERPRETATION: Pembrolizumab in combination with bevacizumab was more efficacious than pembrolizumab monotherapy, with manageable toxicities in platinum-resistant nasopharyngeal carcinoma. If validated in a phase 3 trial, the combination therapy could be a new standard of care in this population of patients. FUNDING: National Medical Research Council of Singapore, National Research Foundation Singapore, Singapore Ministry of Education under its Research Centres of Excellence initiatives, and Merck Sharp & Dohme.

来源:Lancet Oncol,查看原文。版权归原作者所有。

引用

  1. Chong WQ, Low JL, Tay JK, et al. Pembrolizumab with or without bevacizumab in platinum-resistant recurrent or metastatic nasopharyngeal carcinoma: a randomised, open-label, phase 2 trial. Lancet Oncol. 2025. PMID: 39826567. doi:10.1016/S1470-2045(24)00677-6

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。